UTHR – United Therapeutics Corporation
Float Short %
5.06
Margin Of Safety %
-2
Put/Call OI Ratio
0.7
EPS Next Q Diff
-0.14
EPS Last/This Y
0.66
EPS This/Next Y
1.54
Price
503.76
Target Price
540.09
Analyst Recom
1.6
Performance Q
10.26
Relative Volume
0.6
Beta
0.86
Ticker: UTHR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | UTHR | 476.74 | 1.20 | 6.75 | 29196 |
| 2025-12-10 | UTHR | 484.55 | 1.20 | 3.94 | 29214 |
| 2025-12-11 | UTHR | 488.98 | 1.20 | 2.74 | 29216 |
| 2025-12-12 | UTHR | 494.29 | 1.21 | 0.16 | 29356 |
| 2025-12-15 | UTHR | 500.31 | 1.20 | 5.90 | 29486 |
| 2025-12-16 | UTHR | 499.94 | 1.22 | 1.23 | 29743 |
| 2025-12-17 | UTHR | 510.95 | 1.22 | 0.51 | 29813 |
| 2025-12-18 | UTHR | 507.17 | 1.27 | 1.24 | 30060 |
| 2025-12-19 | UTHR | 517.05 | 1.14 | 1.26 | 33971 |
| 2025-12-22 | UTHR | 513.8 | 0.67 | 0.98 | 23414 |
| 2025-12-23 | UTHR | 510.21 | 0.69 | 2.82 | 23877 |
| 2025-12-26 | UTHR | 506.92 | 0.71 | 3.46 | 24383 |
| 2025-12-29 | UTHR | 502.9 | 0.72 | 6.48 | 24553 |
| 2025-12-30 | UTHR | 496.21 | 0.74 | 1.12 | 24873 |
| 2025-12-31 | UTHR | 487.05 | 0.74 | 0.53 | 24975 |
| 2026-01-02 | UTHR | 496.83 | 0.63 | 0.51 | 21452 |
| 2026-01-05 | UTHR | 490.67 | 0.60 | 0.59 | 30756 |
| 2026-01-06 | UTHR | 502.74 | 0.71 | 0.16 | 32027 |
| 2026-01-07 | UTHR | 503.18 | 0.70 | 0.20 | 32682 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-09 | UTHR | 476.36 | 17.1 | 42.8 | 27.10 |
| 2025-12-10 | UTHR | 484.87 | 17.1 | 93.1 | 27.10 |
| 2025-12-11 | UTHR | 488.77 | 17.1 | 73.0 | 27.10 |
| 2025-12-12 | UTHR | 494.05 | 17.1 | 79.6 | 27.10 |
| 2025-12-15 | UTHR | 500.30 | 17.1 | 82.5 | 27.10 |
| 2025-12-16 | UTHR | 500.30 | 17.1 | 54.4 | 27.10 |
| 2025-12-17 | UTHR | 511.02 | 17.1 | 101.6 | 27.10 |
| 2025-12-18 | UTHR | 507.10 | 17.1 | 41.0 | 27.10 |
| 2025-12-19 | UTHR | 517.00 | 17.1 | 95.9 | 27.10 |
| 2025-12-22 | UTHR | 513.82 | 17.1 | 43.8 | 27.10 |
| 2025-12-23 | UTHR | 510.30 | 17.1 | 42.9 | 27.10 |
| 2025-12-26 | UTHR | 506.93 | 17.1 | 25.8 | 27.10 |
| 2025-12-29 | UTHR | 502.89 | 17.1 | 39.1 | 27.10 |
| 2025-12-30 | UTHR | 496.38 | 17.1 | 29.9 | 27.10 |
| 2025-12-31 | UTHR | 486.95 | 17.1 | 18.2 | 27.10 |
| 2026-01-02 | UTHR | 496.48 | 17.1 | 95.2 | 27.10 |
| 2026-01-05 | UTHR | 489.68 | 17.1 | 27.4 | 27.10 |
| 2026-01-06 | UTHR | 502.44 | 17.1 | 109.7 | 27.10 |
| 2026-01-07 | UTHR | 503.76 | 17.1 | 60.5 | 27.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-09 | UTHR | -36.79 | -5.54 | 3.97 |
| 2025-12-10 | UTHR | -36.79 | -5.54 | 4.26 |
| 2025-12-11 | UTHR | -36.69 | -5.54 | 4.26 |
| 2025-12-12 | UTHR | -36.69 | -5.54 | 4.26 |
| 2025-12-15 | UTHR | -37.19 | -5.56 | 4.26 |
| 2025-12-16 | UTHR | -37.51 | -5.56 | 4.26 |
| 2025-12-17 | UTHR | -37.87 | -5.56 | 4.26 |
| 2025-12-18 | UTHR | -37.87 | -5.56 | 4.26 |
| 2025-12-19 | UTHR | -38.14 | -5.56 | 4.26 |
| 2025-12-22 | UTHR | -38.14 | -5.62 | 4.26 |
| 2025-12-23 | UTHR | -38.14 | -5.62 | 4.26 |
| 2025-12-26 | UTHR | -38.20 | -5.62 | 5.06 |
| 2025-12-29 | UTHR | -37.93 | -5.58 | 5.06 |
| 2025-12-30 | UTHR | -38.83 | -5.58 | 5.06 |
| 2025-12-31 | UTHR | -39.38 | -5.58 | 5.06 |
| 2026-01-02 | UTHR | -39.58 | -5.58 | 5.06 |
| 2026-01-05 | UTHR | -39.58 | -5.58 | 5.06 |
| 2026-01-06 | UTHR | -39.63 | -5.58 | 5.06 |
| 2026-01-07 | UTHR | -40.17 | -5.58 | 5.06 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
7.16
Avg. EPS Est. Current Quarter
6.88
Avg. EPS Est. Next Quarter
7.02
Insider Transactions
-40.17
Institutional Transactions
-5.58
Beta
0.86
Average Sales Estimate Current Quarter
817
Average Sales Estimate Next Quarter
817
Fair Value
493.27
Quality Score
100
Growth Score
97
Sentiment Score
76
Actual DrawDown %
3.1
Max Drawdown 5-Year %
-33
Target Price
540.09
P/E
19.09
Forward P/E
16.52
PEG
1.69
P/S
6.93
P/B
3.28
P/Free Cash Flow
19.33
EPS
26.39
Average EPS Est. Cur. Y
27.1
EPS Next Y. (Est.)
28.64
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
40.65
Relative Volume
0.6
Return on Equity vs Sector %
-7.8
Return on Equity vs Industry %
12.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
60.5
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading